Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly vs 3-Weekly Carboplatin/Paclitaxel in Advanced Ovarian Cancer
NCT05963334Phase 2Completed
- Sponsor
- Cairo University
- Start
- Jan 2015
- Primary completion
- Nov 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of carboplatin and paclitaxel in epithelial ovarian cancer (EOC) (2 arms), sponsored by Cairo University. Primary endpoints: Routine blood work and tumor markers, Additional kidney and anemia biomarkers and 1 more. Started Jan 2015; status: completed.
02
Drugs
carboplatinpaclitaxel
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT05963334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963334.